OVI 117

Drug Profile

OVI 117

Alternative Names: Derivative of FduMP/5-FU (OVI-117); L-117; L-nucleoside conjugate (OVI-117); OVI-117

Latest Information Update: 02 Jun 2016

Price : $50

At a glance

  • Originator Genencor International; Lipitek International
  • Developer OncoVista
  • Class Antineoplastics; Drug conjugates; Nucleosides
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 29 Apr 2016 Oncovista announces intention to terminate its licence for OVI 117
  • 18 Jun 2015 Phase-I clinical trials in Colorectal cancer in USA (IV)
  • 01 Apr 2013 Phase I development is ready to commence in the USA upon availability of additional financing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top